Package Leaflet: Information for the User
Isentress 25mg Chewable Tablets
Isentress 100mg Chewable Tablets
raltegravir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
If you are the parent of a child taking Isentress, please read this information carefully with your child.
Contents of the pack
What Isentress is
Isentress contains the active substance raltegravir. Isentress is an antiviral medicine that acts against the human immunodeficiency virus (HIV). This is the virus that causes acquired immune deficiency syndrome (AIDS).
How Isentress works
The virus produces an enzyme called HIV integrase, which helps the virus to enter the cells of the body and multiply. Isentress prevents this enzyme from working. When used with other medicines, Isentress can reduce the amount of HIV in the blood (this is called your “viral load”) and increase the number of CD4 cells (a type of white blood cell that plays an important role in keeping the immune system healthy to help fight infection). By reducing the amount of HIV in the blood, it can improve the functioning of your immune system. This means your body can fight off infections better.
When Isentress should be used
Isentress is used to treat patients who are infected with HIV. Your doctor has prescribed Isentress to help control the HIV infection you have.
Do not take Isentress:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start taking Isentress.
Remember that Isentress does not cure HIV infection. This means you may still get illnesses or infections related to HIV. You must keep seeing your doctor regularly while taking this medicine.
Mental health problems
Tell your doctor if you have a history of depression or mental health problems. Depression, including thoughts and behaviors of suicide, has been seen in some patients taking this medicine, especially in patients with a history of depression or mental health problems.
Bone problems
Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of time taking combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immune system suppression, increased body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, pain, and difficulty moving. If you experience any of these symptoms, see your doctor.
Liver problems
Tell your doctor, pharmacist, or nurse if you have had liver problems in the past, including hepatitis B or C. Your doctor may assess the severity of your liver disease before deciding if you can take this medicine.
Infections
If you notice any symptoms of infection, such as fever and/or feeling unwell, tell your doctor, pharmacist, or nurse immediately. Some patients with advanced HIV infection who have previously had opportunistic infections may show signs and symptoms of inflammation from previous infections soon after starting treatment for HIV. It is believed that these symptoms are due to the improvement in the body's immune response, which enables the body to fight off infections that may have been present without causing obvious symptoms.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may occur after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremor, or hyperactivity, tell your doctor immediately to receive the necessary treatment.
Muscle problems
Contact your doctor, pharmacist, or nurse immediately if you notice unexplained muscle pain, tenderness, or muscle weakness while taking this medicine.
Skin problems
Contact your doctor immediately if you develop a rash. Serious and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking this medicine.
Other medicines and Isentress
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, with or without a prescription.
Isentress may interact with other medicines.
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take:
Taking Isentress with food and drinks
See section 3.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you are pregnant or breastfeeding, ask your doctor, pharmacist, or nurse for advice before taking any medicine.
Driving and using machines
Do not drive, operate machinery, or ride a bicycle if you feel dizzy after taking this medicine.
Isentress 25 mg chewable tablet
Isentress 25mg chewable tablet contains fructose
This medicine contains up to 0.54 mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 25mg chewable tablet contains sorbitol
This medicine contains up to 1.5 mg of sorbitol (E 420) in each tablet.
Isentress 25mg chewable tablet contains sucrose
This medicine contains up to 3.5 mg of sucrose in each 25 mg chewable tablet.
Sucrose may damage teeth.
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Isentress 25mg chewable tablet contains aspartame
This medicine contains up to 0.47 mg of aspartame (E 951) in each 25 mg chewable tablet, which is equivalent to up to 0.05 mg of phenylalanine. Aspartame is a source of phenylalanine that may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Isentress 25mg chewable tablet contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Isentress 100 mg chewable tablet
Isentress 100mg chewable tablet contains fructose
This medicine contains up to 1.07 mg of fructose in each tablet.
Fructose may damage teeth.
Isentress 100mg chewable tablet contains sorbitol
This medicine contains up to 2.9 mg of sorbitol (E 420) in each tablet.
Isentress 100mg chewable tablet contains sucrose
This medicine contains up to 7 mg of sucrose in each 100 mg chewable tablet.
Sucrose may damage teeth.
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Isentress 100mg chewable tablet contains aspartame
This medicine contains up to 0.93 mg of aspartame (E 951) in each 100 mg chewable tablet, which is equivalent to up to 0.10 mg of phenylalanine. Aspartame is a source of phenylalanine that may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Isentress 100mg chewable tablet contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. If you are not sure, check with your doctor, pharmacist, or nurse. Isentress must be used in combination with other medicines for HIV.
The 100 mg chewable tablet can be divided into two equal halves. However, it is recommended to avoid splitting the tablets whenever possible.
How much to take
Dose for children between 2 and 11years of age
Your doctor will recommend the appropriate dose of chewable tablets based on the child's age and weight. This dose should not exceed 300 mg twice a day. Your doctor will tell you how many chewable tablets the child should take.
Isentress is also available as a 400 mg tablet, a 600 mg tablet, and an oral suspension.
Do not switch between the chewable tablet, the oral suspension, the 600 mg tablet, or the 400 mg tablet without first consulting your doctor, pharmacist, or nurse.
Children should attend scheduled visits with their doctor as their dose of Isentress may need to be adjusted as they get older, grow, or gain weight. Your doctor may also want to prescribe the 400 mg tablet when they are able to swallow a tablet.
This medicine can be taken with or without food or drinks.
If you take more Isentress than you should
Do not take more tablets than your doctor has recommended. If you take more tablets than recommended, talk to your doctor.
If you forget to take Isentress
If you stop taking Isentress
It is important that you take Isentress exactly as your doctor has told you. Do not change the dose or stop taking this medicine without first consulting your doctor, pharmacist, or nurse. Do not stop taking it, because:
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Severe Adverse Effects– these are rare (may affect up to 1 in 100 people)
See a doctor immediately if you notice any of the following adverse effects:
See a doctor immediately if you notice any of the above-mentioned adverse effects.
Frequent: the following adverse effects may affect up to 1 in 10 people
Rare: the following adverse effects may affect up to 1 in 100 people
Other adverse effects in children and adolescents
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Isentress Composition
The active ingredient is raltegravir.
25 mg chewable tablets:
Each chewable tablet contains 25 mg of raltegravir (potassium salt).
The other ingredients are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
100 mg chewable tablets:
Each chewable tablet contains 100 mg of raltegravir (potassium salt).
The other ingredients are: hydroxypropylcellulose, sucralose, sodium saccharin, sodium citrate dihydrate, mannitol (E 421), red iron oxide, yellow iron oxide, monoammonium glycyrrhizinate, sorbitol (E 420), fructose, natural and artificial flavors (orange, banana, and masking), aspartame (E 951), sucrose, crospovidone Type A, magnesium stearate, sodium stearyl fumarate, ethylcellulose 20 cP, ammonium hydroxide, medium-chain triglycerides, oleic acid, hypromellose 2910/6cP, and macrogol/PEG 400.
Product Appearance and Package Contents
Isentress 25 mg chewable tablets:
Light yellow chewable tablet, orange and banana flavor, round, with the MSD corporate logo on one side and "473" on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains a desiccant.
Isentress 100 mg chewable tablets:
Light orange chewable tablet, orange and banana flavor, oval, scored on both sides, engraved on one side with the MSD corporate logo and the code "477" and without engraving on the other side.
One pack size is available: 1 bottle with 60 tablets. The bottle contains a desiccant.
Marketing Authorization Holder and Manufacturer
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel: +32(0)27766211 | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 2780 247 |
| Luxembourg/Luxemburg MSD Belgium Tel: +32(0)27766211 |
Czech Republic Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 | Hungary MSD Pharma Hungary Kft. Tel: +36 1 888 5300 |
Denmark MSD Danmark ApS Tel: +45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) |
Germany MSD Sharp & Dohme GmbH Tel: +49 (0) 89 20 300 4500 | Netherlands Merck Sharp & Dohme B.V. Tel: 0800 9999000 (+31 23 5153153) |
Estonia Merck Sharp & Dohme OÜ Tel: +372 614 4200 | Norway MSD (Norge) AS Tel: +47 32 20 73 00 |
Greece MSD Α.Φ.Ε.Ε. Tel: +30 210 98 97 300 | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Poland MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 |
France MSD France Tel: +33 (0) 1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465700 |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 520 4201 |
Iceland Vistor ehf. Tel: + 354 535 7000 | Slovakia Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Finland MSD Finland Oy Tel: +358 (0)9 804 650 |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Latvia SIA Merck Sharp & Dohme Latvija Tel: + 371 67025300 |
Date of Last Revision of this Leaflet:<{MM/AAAA}><{month YYYY}>.
Detailed information about this medicine is available on the European Medicines Agency website: https://www.ema.europa.eu.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ISENTRESS 100 MG CHEWABLE TABLETS – subject to medical assessment and local rules.